A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

Conditions

Colon | Rectum

Phase 1B/2

What is the purpose of this trial?

A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) who experienced disease progression during or following two lines of treatment.

Eligible patients will be assigned to one of several treatment arms.

  • Trial with
    F. Hoffman-La Roche Ltd
  • Start Date
    10/02/2018
  • End Date
    03/31/2020

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Christina Wiess

  • Last Updated
    12/02/2018
  • Study HIC
    #2000023122